References
- Swenson W T, Wooldridge J E, Lynch C F, Forman-Hoffman V L, Chrischilles E, Link B K. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005; 23: 5019–5026
- Fisher R I, LeBlanc M, Press O W, Maloney D G, Unger J M, Miller T P. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447–8452
- Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732
- van Oers M H, Klasa R, Marcus R E, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295–3301
- Friedberg J W, Taylor M D, Cerhan J R, et al. Follicular Lymphoma in the United States: First Report of the National LymphoCare Study. J Clin Oncol 2009, (in press)
- Leoni L M, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14: 309–317
- Friedberg J W, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008; 26: 204–210
- Kahl B, Bartlett N L, Leonard J P, et al. Bendamustine is safe and effective in patients with rituximab-refractory indolent B-cell non-Hodgkin lymphoma. Blood 2007; 110: 406a
- Rummel M J, Al-Batran S E, Kim S Z, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383–3389
- Robinson K S, Williams M E, van der Jagt R H, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4473–4479
- Rummel M J, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first line treatment of patients with indolent and mantle cell lymphomas–first interim results of a randomized phase III study of the StiL. Blood 2007; 110: 120a
- Sanchez-Gonzalez B, Garcia M, Serrano S, Besses C, Salar A. Bendamustine-containing immunochemotherapy is active in transformed follicular lymphoma with overexpression of p53. Leuk Lymphoma 2009; 50: 455–456
- Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916